Program Overview

Abstracts Discussed

Current first-line treatment of acute lymphoblastic leukemia (ALL) comprises induction, consolidation, intensification, and maintenance chemotherapy. Asparaginase is a critical component during induction, consolidation and intensification in pediatric and adult/young adult populations leading to improvements in event-free and overall survival. Yet the toxicity profile of asparaginase and drug-shortages both contribute to insufficient exposure to asparaginase and suboptimal outcomes in ALL. Appropriate management of patients with ALL is challenging, particularly for adult-focused HCPs unfamiliar with pediatric and adolescent and young adults (AYA) protocols.

In order to address these educational needs, this CME-certified activity will focus on key studies presented at ASH 2021; including results from the Graaph-2014 (studied the omission of HD-AraC during consolidation of Ph-positive ALL patients treated with nilotinib and low-intensity chemotherapy) and the UKALL14 (assessment of addition of nelarabine to standard chemotherapy in T-cell ALL) trials.

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study.

Rousselot P, Chalandon Y, Chevret S, et al., et al. Blood.2021;138(Supplement 1):512

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006).

Rowntree CJ, Kirkwood AA, Clifton-Hadley L, et al. Blood.2021;138(Supplement 1):366

Target Audience

This education activity has been designed to meet the needs of:

• Hematologists, medical oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other HCPs interested in the treatment of patients with ALL

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period of June 15, 2022 through June 15, 2023, participants must:

• Read the learning objectives and faculty disclosures

• Complete the pretest

• Study the educational activity

• Complete the posttest and the evaluation form

A statement of credit will be issued only upon successful completion (75% passing score) and receipt of the activity posttest and evaluation form. Certificates will be sent via email within four weeks of receipt of a completed evaluation form.

Accreditation

Physician Continuing Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this Other activity (multi-channel video and discussion) for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)